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The role of reductive and oxidative metabolism in the toxicity of
mitoxantrone, adriamycin and menadione in human liver derived Hep G2
hepatoma cells
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Summary The cytotoxic properties of quinones, such as menadione, are mediated through one electron
reduction to yield semi-quinone radicals which can subsequently enter redox cycles with molecular oxygen
leading to the formation of reactive oxygen radicals. In this study the role of reduction and oxidation in the
toxicity of mitoxantrone was studied and its toxicity compared with that of adriamycin and menadione. The
acute toxicity of mitoxantrone was not mediated through one-electron reduction, since inhibition of the
enzymes glutathione reductase and catalase, responsible for protecting the cells against oxidative damage, did
not affect its toxicity. Adriamycin was the most potent inhibitor of protein and RNA synthesis of the three
quinones. Menadione, at concentrations up to 25 ftM, did not inhibit either protein or RNA synthesis unless
dicoumarol, an inhibitor of DT-diaphorase, was also present. The two-electron reduction of menadione by
DT-diaphorase is therefore a protective mechanism in the cell. This enzyme also protected against the toxicity
of high concentrations (100pM) of mitoxantrone. The inhibitory effect of mitoxantrone, but not of menadione
or adriamycin, on cell growth was prevented by inhibiting the activity of cytochrome P450-dependent mixed
function oxidase (MFO) system using metyrapone. This suggests that mitoxantrone is oxidised to a toxic
intermediate by the MFO system.
The quinoid anthracycline drug adriamycin is one of the
most widely prescribed drugs in the treatment of a wide
range of human malignancies (Arcamone, 1984). However,
the cumulative dose-dependent cardiomyopathy produced by
the drug severely restricts its therapeutic usefulness (Minow
et al., 1975) and this problem has lead to the development of
new structurally related anthraquinone drugs. One of these is
mitoxantrone, which is currently used in advanced breast
cancer and acute leukaemias (Cornbleet et al., 1984).
Although mitoxantrone does not exhibit the same broad
spectrum of anti-tumour activity as does adriamycin, the
incidence and severity of cardiotoxicity is markedly reduced
(Smith, 1983).
The mechanism of action of mitoxantrone is uncertain.
There is evidence to suggest that, in common with the
anthracyclines, nucleic acids are among the principal cellular
targets of the drug (Lown et al., 1985). Since mitoxantrone
contains a quinone functional group within its structure it
has been considered to undergo activation by metabolic
reduction similar to adriamycin (Mimnaugh et al., 1982;
Kharasch & Novak, 1983). However, evidence exists which
indicates that mitoxantrone is metabolised by cytochrome
P-450 dependent mixed function oxidase (MFO) to yield a
reactive intermediate which may contribute to its biological
activity (Wolf et al., 1986). In this study we have investigated
the role of reduction and oxidation in the activation of
mitoxantrone to toxic reactive metabolites in human liver
derived Hep G2 hepatoma cells using specific enzyme
inhibitors. The toxicity of mitoxantrone has been compared
with that of the model quinone drug, menadione (2-methyl-1,
4-naphthoquinone), which is known to be mediated by reduc-
tive metabolism leading to the formation of semiquinone
radicals and reactive oxygen species (Thor et al., 1982).
The metabolism of quinones can proceed by either one-
electron reduction to semiquinone radicals or by two-electron
reduction to yield the more stable hydroquinones (Iyanagi &
Yamazaki, 1970). The latter pathway is considered to be a
detoxifying process and is catalysed by NAD(P)H: (quinone
acceptor) oxidoreductase (also known as DT-diaphorase)
(Lind et al., 1982). One electron reduction is carried out
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mainly by the action of the enzymes NADPH-cytochrome c
reductase and NADH cytochrome b5 reductase (lyanagi &
Yamazaki, 1970). The semiquinones generated by one-
electron reduction participate in deleterious redox cycling
with molecular oxygen resulting in the formation of various
reactive oxygen species, such as superoxide anion, hydrogen
peroxide, hydroxyl radical and singlet oxygen. This redox
cycling may ultimately lead to oxidative stress and cell tox-
icity. For instance, Thor et al. (1982) observed that exposure
of isolated rat hepatocytes to menadione resulted in the
production of superoxide, oxidation of glutathione and loss
of cell viability. Cellular protection against the effects of
reactive oxygen species is provided by the activities of the
enzymes glutathione reductase, glutathione peroxidase,
catalase and superoxide dismutase (Kappus, 1986).
The aim of this study was to investigate the mechanism(s)
responsible for activation of mitoxantrone to cytotoxic
metabolites and compare its toxicity with that of menadione
and adriamycin. The results provide evidence that mitoxant-
rone may be activated to a toxic metabolite by cytochrome
P450 dependent oxidation and that one-electron reduction is
not involved in the mechanism of toxicity. The relevance of
these results to improving chemotherapy regimes is discussed.
Materials and methods
Materials
Reduced glutathione, dicoumarol, metyrapone and 1,2-
aminotriazole were obtained from Sigma. Fetal calf serum
was from Gibco and Dulbecco's modification of Eagle's
medium was from Flow Laboratories. Mitoxantrone was a
generous gift from Lederle Laboratories; adriamycin from
Farmitalia Carlo Erba and 1,3-bis(2-chloroethyl)- I -
nitrosourea from Bristol Myers. Hep G2 cells were obtained
by Dr W.T. Melvin, Department of Biochemistry, Aberdeen
University, from Professor C.N. Hales, Department of
Clinical Biochemistry, Addenbrooke's Hospital, Cambridge.
Culture ofHep G2 cells
Hep G2 cells were routinely grown in monolayer or multi-
layer culture in Dulbecco's modified Eagle's medium supp-
lemented with 10% (v/v) fetal calf serum. They were grown
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in a humidified atmosphere of 5% CO2 in air and subcul-
tured every seven days at a split ratio of 1 to 3 (seeding
density 5 x 104 cells cm2.
Quinone toxicity assessed by leakage oflactate dehydrogenase
and GSH depletion
Confluent monolayers of cells (7 days after passage) were
treated with either 50l5M menadione or 100JLM mitoxantrone
in Sml serum-free medium for 6 h. After this time the
reduced glutathione (GSH) content of the cells was deter-
mined by the fluorimetric method of Hissin and Hilf (1976)
and the lactate dehydrogenase activity in the medium was
measured as described previously (Anuforo et al., 1978). The
effect of various enzyme inhibitors and of prior GSH deple-
tion on the toxicity of the two quinone drugs was inves-
tigated.
Dicoumarol 30plM or aminotriazole 5 mM was added to
inhibit intracellular DT-diaphorase (Lind et al., 1982) or
catalase activities (Starke & Farber, 1985) respectively. 1,3-
bis(2-chlorethyl)-1-nitrosourea (BCNU) is a relatively specific
inhibitor of glutathione reductase (Babson & Reed, 1981).
However, this agent depletes intracellular GSH in addition to
inhibiting glutathione reductase. Eklow and co-workers
developed a BCNU-treated isolated rat hepatocyte system in
which glutathione reductase was inhibited, but GSH levels
were normal (Eklow et al., 1984) and this protocol has been
modified for use with Hep G2 cells as follows. Hep G2 cells
were exposed to 75 ylM BCNU for 2 h in monolayer culture
in serum free medium. The cultures were then washed and
incubated in medium containing 10% (v/v) fetal calf serum
supplemented with 0.25 mM L-cysteine and GSH resynthesis
allowed to proceed for a further 2 h. The cells were then
exposed to either menadione or mitoxantrone for 6 h. After
BCNU treatment the activity of glutathione reductase was
37.0 ± 2.6 jsmol min-' 106 cells-' (n =4) compared with
75.6 ± 3.2 tmol min-' 106 cells-' (n =4) in control cells
(P<0.01, by non-paired Student's t test). GSH content was
9.0 ± 1.9 nmol 106 cells-' (n = 3) in BCNU-treated cells com-
pared with 8.0 ± 1.9 nmol 106 cells-' (n = 3) in the controls.
To deplete intracellular GSH, monolayers were pretreated
with 0.5 mM DL-buthionine-SR-sulphoximine (BSO), a
specific inhibitor of y-glutamyl cysteine synthetase (Griffith &
Meister, 1979), for 24 h before exposure to the quinones.
After BSO treatment intracellular GSH was 3.8 ± 0.5 nmol
106cells-' (n = 5) compared with 12.6 ± 1.0 nmol 106 cells-'
in control flasks (n = 5) (P<0.01, by non-paired Student's t
test).
Effect ofquinones on cellgrowth, protein synthesis and RNA
synthesis
Cells were allowed to attach in culture for 10 h after passage
before exposure to either menadione (0-25 pM), mitoxan-
trone (0-25 tiM) or adriamycin (0-25 tM) in 5 ml serum-free
medium for 4 h. After this time the cells were washed and
allowed to grow in medium containing 10% (v/v) fetal calf
serum for 48 h.
Cell growth was assessed both by cell numbers and by
protein content. To determine cell numbers suspensions were
prepared by treating the cultures with 1: 5 solution of 0.25%
(w/v) trypsin: 0.02% (w/v) versene in phosphate buffered
saline, pH 7.4. Protein content was measured by the method
of Lowry et al. (1951) after solubilising the monolayers with
0.5 M NaOH.
For the measurement ofprotein synthesis and RNAsynthesis
cells were exposed to 1 JLCi per flask tritiated leucine or uridine,
respectively, for 16 h. After this time thecells werewashed twice
with Krebs-Henseleit buffer, pH 7.4, containing 10 mM Hepes,
and flooded with either 0.5 mM cold leucine or 0.5 mM uridine
for 5 min. Acid soluble radioactivity was removed by treatment
with 10% (w/v) trichloroacetic acid for 10 min and the cells
solubilised for 18 h with 0.5 M NaOH before measuring the
incorporation of tritium into the cell protein and RNA by
scintillation counting.
The effect of inhibition of DT-diaphorase by 30tLM
dicoumarol and inhibition of MFO by 0.5 mM metyrapone on
the toxicity of the quinones was assessed by adding the
inhibitors to the flask at the same time as the drugs.
Results
Exposure of Hep G2 cells to either 5011M menadione or
100gtM mitoxantrone caused an increase in the lactate dehyd-
rogenase activity of the culture medium (Figure 1). The
presence of dicoumarol, an inhibitor of DT-diaphorase,
potentiated the toxicity of both quinones, although the effect
on that of menadione was much greater. Inhibition of
catalase by 1,2-aminotriazole and of glutathione reductase by
BCNU exacerbated the effect of menadione on lactate dehyd-
rogenase leakage but had no effect on the lactate dehyd-
rogenase leakage from cells treated with mitoxantrone.
Depletion of intracellular GSH by BSO had a small effect on
the viability of cells exposed to both quinones.
Table I shows that menadione caused depletion of intracel-
lular GSH levels which was markedly potentiated by the
presence of dicoumarol. In contrast, mitoxantrone caused a
slight decrease in GSH levels which was not altered by
dicoumarol.
The relative inhibitory potency of the three quinone drugs
on cell growth, protein and RNA synthesis is shown in
Figures 2, 3 and 4. Menadione was a less potent inhibitor of
cell growth than either adriamycin or mitoxantrone and this
quinone caused little inhibition of either protein or RNA
synthesis at concentrations up to 251LM. The cell number
data indicated a greater inhibition of cell growth by
adriamycin than by mitoxantrone, whereas the protein con-
tent data showed the opposite relationship. The reason for
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Figure 1 Leakage of lactate dehydrogenase (LDH) activity from
cells treated with either 50ZlM menadione (M) or 100 tiM mitox-
antrone (MZ) in the presence or absence of dicoumarol (DIC),
1,2-aminotriazole (AT), BCNU and buthionine sulfoximine
(BSO). Results are the means of between 4 and 8 experiments
and error bars represent s.e.m. 'P<0.01, by one way analysis of
variance followed by Dunnett's test. Significance values refer to
differences between cells treated with either menadione or mitox-
antrone alone and in the presence of the inhibitors.568 S.J. DUTHIE & M.H. GRANT
Table I GSH depletion induced by menadione and mitoxantrone
GSH levels
Incubations (% control)
30tLM dicoumarol 98.9 4.0 (5)
50ZtM mendione 37.8 ± 5.2 (8)
50 !iM menadione +
30tLM dicoumarol 6.6 ± 2.5 (5)'
100liM mitoxantrone 71.4 ± 7.9 (5)
100 AM mitoxantrone +
30gM dicoumarol 83.1 ± 10.3 (6)
The cells were exposed to the drugs for 6 h at 37°C under the
conditions described in Methods. Results are expressed as % of the
GSH content of control untreated cells, and are shown as mean +
s.e.m. with the number of experiments in parentheses. P<0.005, by
unpaired Student's t test. Significance value refers to differences in
GSH depletion by menadione in the presence and absence of
dicoumarol.
this discrepancy is unclear at present but it may be that cells
exposed to mitoxantrone are more susceptible to trypsin
treatment than those exposed to adriamycin. Although both
adriamycin and mitoxantrone inhibited protein synthesis to
similar extents, the former drug was a more potent inhibitor
of RNA synthesis than was mitoxantrone.
Figure 5 shows that inhibition of DT-diaphorase activity
by dicoumarol potentiated the effect of menadione on cell
growth, protein and RNA synthesis. Dicoumarol had no
significant effect on the response of the cells to mitoxantrone,
and potentiated the effect of adriamycin on protein synthesis
but not on cell growth or RNA synthesis. Figure 6 shows
that inhibition of MFO activity by metyrapone prevented the
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Figure 3 The effect of the quinones on protein synthesis. 0,
menadione; A, adriamycin; 0, mitoxantrone. Results are means
of at least 4 experiments. Error bars represent s.e.m.
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Figure 2 The effect of the quinones on cell grow
cell number (a) and protein content (b). 0,
adriamycin; 0, mitoxantrone. Results are the me;
experiments. Error bars represent s.e.m.
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20
y Figure 4 The effect of the quinones on RNA synthesis. 0,
menadione; A, adriamycin; 0, mitoxantrone. Results are means
of at least 4 experiments. Error bars represent s.e.m.
20 25
inhibition of cell growth by mitoxantrone but did not alter
the effect of menadione or adriamycin. Metyrapone did not
alter the inhibitory effect of any of the three quinones on
protein synthesis (data not shown).
Discussion
The results of this study indicate that in human liver derived
Hep G2 cells mitoxantrone-induced loss in cell viability is not
mediated through the one-electron reduction/oxidative stress
mechanism which is accepted for the cytotoxicity of quinone
drugs such as menadione. In support of this inhibition of the
enzymes catalase and glutathione reductase, responsible for
protecting the cells from oxidative damage, did not affect the
leakage of lactate dehydrogenase from Hep G2 cells treated
with mitoxantrone, whereas it exacerbated the effect of
menadione.
20 25 Dicoumarol potentiated the effect of both quinones on
leakage of lactate dehydrogenase activity indicating that DT-
th measured by diaphorase activity is involved in metabolising both drugs
menadione; A, and provides a protective mechanism in the cell. Depletion of
ans of at least 4 GSH by BSO increased the toxicity of the quinones only
slightly, suggesting that in these cultured cells intracellularQUINONE TOXICITY IN HUMAN HEPATOMA CELLS
GSH content may be less important than DT-diaphorase in
protecting against quinone-induced toxicity.
The toxicity of menadione in the Hep G2 cells was accom-
panied by marked depletion of GSH, which was exacerbated
by the presence of dicoumarol. Menadione-induced GSH
depletion has been reported previously (Thor et al., 1982;
Morrison et al., 1985) and is due primarily to oxidation to
the dimer GSSG by the products of oxidative stress
generated during the one-electron reduction of the quinone
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Figure 5 The effect of 30 laM dicoumarol on the inhibition of cell
growth (a, cell number; b, protein content); protein synthesis (c)
and RNA synthesis (d) by menadione (M), mitoxantrone (MZ)
and adriamycin (ADM). Shaded bars on the histograms represent
results in the presence of dicoumarol. For cell growth and protein
synthesis the concentrations of quinones used were 25 JM
menadione, 5 1AM mitoxantrone and 10 JAM adriamycin. For RNA
synthesis the same concentrations of menadione and mitoxant-
rone were used whereas I JAM adriamycin was used. Results are
the means of between 4 and 9 experiments, and error bars
represent s.e.m. P<0.05, **P<0.005, by unpaired Student's t
test. Significance values refer to differences observed in the
presence and absence of dicoumarol.
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Figure 6 The effect of 0.5 mM metyrapone on the inhibition of
cell growth by menadione (M), adriamycin (ADM) and mitoxant-
rone (MZ). Shaded bars on the histograms represent results in
the presence of metyrapone. The concentrations of quinones used
were 25 JAM menadione, 5fM mitoxantrone and 10gM
adriamycin. Results are the mean of 4 experiments, and error
bars represent the s.e.m. 'P<0.02, by unpaired Student's t test.
Significance value refers to differences observed in the presence
and absence of metyrapone.
(Di Monte et al., 1984). In contrast, mitoxantrone caused
only a slight decrease in intracellular GSH, which was
unaffected by the presence of dicoumarol. Mitoxantrone has
been reported to form glutathione conjugates and this may
account for the depletion of GSH (Wolf et al., 1986). The
glutathione conjugates of menadione are reported to have
similar redox properties to the parent (Ross et al., 1985;
Takahashi et al., 1987), so this metabolic pathway may not
necessarily lead to detoxification of quinone drugs. Our
previous experiments support the suggestion that menadione
and mitoxantrone deplete GSH by different mechanisms
(Duthie & Grant, 1989). We have shown that in Hep G2 cell
suspensions GSH depletion precedes cell death in the case of
menadione, but not of mitoxantrone.
The concentrations of mitoxantrone which cause loss of
cell viability are higher than those which inhibit cell growth,
protein and RNA synthesis and probably represent non-
specific cytotoxicity. Menadione is the least effective inhibitor
of cell growth of the three quinones tested, and it has little
effect on protein or RNA synthesis at concentrations up to
25 JAM. Adriamycin is a more potent inhibitor of RNA syn-
thesis, and to a lesser extent of protein synthesis than mitox-
antrone. Both adriamycin and mitoxantrone are known to
intercalate into DNA bases (Lown, 1983; Kapuscinski &
Darzynkiewicz, 1985) inhibiting DNA template function and
causing subsequent inhibition of RNA and protein synthesis.
This interaction of adriamycin and DNA is considered to be
one of the principal mechanisms of cytotoxicity (Potmesil et
al., 1984; Lown, 1983). In contrast, there appears to be little
correlation between the intercalative binding of mitoxantrone
and pharmacological activity (Kapuscinski & Darzynkiewicz,
1985). Another type of interaction with DNA may be more
important in the case of mitoxantrone. For example, both
quinones can also cause DNA damage by stabilising the
binding of topoisomerase II to DNA (Pommier et al., 1985)
and mitoxantrone has been shown to affect topoisomerase
activity in breast cancer cells (Crespi et al., 1986). There is
little doubt that the interaction of the two drugs with DNA
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is crucial to the mechanism of their antitumour activity, but
the exact nature of this interaction is as yet unclear.
The effects of menadione on the cell growth rate, protein
and RNA synthesis were all potentiated by dicoumarol,
indicating the protective role of DT-diaphorase. Although
the acute cytotoxicity of 100tLM mitoxantrone was also
potentiated by dicoumarol (Figure 1) its effect on cell growth
rate, protein and RNA synthesis (at 5pM) were not affected.
This may be because at the lower mitoxantrone concentra-
tions the cellular defences are not overwhelmed even when
DT-diaphorase is inhibited. The effect of adriamycin on cell
growth rate and RNA synthesis is not affected by
dicoumarol, but the effect on protein synthesis was repro-
ducibly potentiated. This suggests that adriamycin toxicity
may be mediated by more than one mechanism.
The prevention of the cytostatic effect of mitoxantrone by
the presence of metyrapone is an important observation. We
have previously demonstrated that the cytotoxicity of this
quinone could be enhanced by inhibiting epoxide hydrolase
(Duthie & Grant, 1989). Wolf et al. (1986) also found that in
rat liver microsomes mitoxantrone could be metabolised by
the MFO system, and that the metabolite formed was subse-
quently conjugated with glutathione. These lines of evidence
suggest that mitoxantrone may be oxidised by the MFO
system to form an epoxide, which is detoxified by glutathione
conjugation. Although metyrapone did not affect the toxicity
of either menadione or adriamycin, there have been reports
of the activation of quinones to unidentified cytotoxic
intermediates by the MFO system previously (Chesis et al.,
1984). Furthermore, oxidation of mitoxantrone by
horseradish peroxidase has been demonstrated previously by
electron paramagnetic resonance studies (Reszka et al., 1986).
The antitumour activity of adriamycin is not generally
thought to involve reduction of the drug (Butler & Hoey,
1987) whereas there is considerable evidence to suggest that
the cardiotoxicity is mediated through one-electron reduction
to the adriamycin semiquinone free radical with the
associated production of reactive oxygen species (Mimnaugh
et al., 1982, 1983; Doroshow & Davies, 1983). According to
the results of the present study mitoxantrone does not
undergo significant one-electron reduction. This is in agree-
ment with previous studies using purified enzyme stystems
and human liver which have shown the relative difficulty of
enzymically reducing mitoxantrone compared with
adriamycin (Kharasch & Novak, 1981; Doroshow & Davies,
1983; Basra et al., 1985). If the biological activation of
mitoxantrone is by oxidation catalysed by the MFO system
this, together with the absence of any significant reduction of
the drug by NADPH-cytochrome c reductase, may explain
why cardiac tissue is relatively resistant to mitoxantrone
toxicity. Heart tissue has a very low cytochrome P450 con-
tent, whereas the activity of cardiac NADPH-cytochrome c
reductase supports the reduction of adriamycin efficiently
(Mimnaugh et al., 1983). In addition it may be of therapeutic
value to administer an inducing agent, such as phenobar-
bitone, which increases MFO activities, concomitantly with
mitoxantrone therapy. The activation of mitoxantrone to
toxic metabolites by the MFO system is currently being
investigated further.
This study was supported by the Wellcome Trust and by Grampian
Health Board.
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